1,904 results on '"Vose, Julie M."'
Search Results
102. Poster: CLL-217 Patient Characteristics and Time to Next Treatment With Ibrutinib and Anti-CD20 Monotherapy as First-Line Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
103. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
104. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 + indolent NHL: Correlation between clinical responses and AUC pharmacokinetics
105. Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma
106. Chapter 86 - Mantle Cell Lymphoma
107. Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma
108. American Society of Hematology: 64th Annual Meeting Review
109. ABCL-191 Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
110. Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
111. Diagnosis and Treatment of Non-Hodgkin’s Lymphoma of Adults
112. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study.
113. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
114. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
115. Impact of Conditioning Regimen on Outcome of 2-Year Disease-Free Survivors of Autologous Stem Cell Transplantation for Hodgkin Lymphoma
116. Salvage Second Hematopoietic Cell Transplantation in Myeloma
117. Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
118. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
119. Management of indolent lymphoma: Where are we now and where are we going
120. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
121. Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure
122. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis
123. Post Autologous Stem Cell Transplant (ASCT) Hepatitis B Virus (HBV) Seroconversion in Multiple Myeloma (MM) Patients: Single Institution Experience on Rates and Contributing Factors
124. Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium
125. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-up of Zuma-1 Cohort 6 (C6)
126. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
127. 18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair
128. The High Cost of Oral Anticancer Drugs: What Does the Future Hold?
129. Improving Cancer Survivorship Care Is a Team Sport
130. Comparison of Front-Line Chemotherapy for Intermediate Grade and Follicular Non-Hodgkin’s Lymphoma Using the CAP-BOP Regimens
131. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project
132. Peripheral T-cell lymphoma
133. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
134. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
135. Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response
136. Mutation and Genomic Deletion Status of ataxia telangiectasia mutated (ATM) and p53 Confer Specific Gene Expression Profiles in Mantle Cell Lymphoma
137. Effect of Time to Relapse on Overall Survival in MCL Patients Following Autologous Hematopoietic Cell Transplantation
138. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial
139. Contributors
140. What Do American Board of Internal Medicine Recertification Exams Measure?
141. 2024 Statistics May Impact Next Decade of Cancer Treatment.
142. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
143. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
144. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part II: Chronic Leukemias, Myeloproliferative Neoplasms, and Lymphoid Malignancies
145. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes
146. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
147. The present status of therapy for patients with aggressive non-Hodgkin’s lymphoma
148. Bone marrow transplantation for Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma
149. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers
150. A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.